24h de science
Article in French - "Médicaments à l'eau, danger"
Venez visionner le reportage intitulé «Des médicaments dans l'eau» présenté à l'émission La vie en vert, à Télé-Québec. La diffusion sera suivie d'une période de questions avec le Dr Daniel Cyr, de l'Institut national de la recherche scientifique, qui a participé au reportage. Finalement, pour les gens intéressés, nous diffuserons le film Homo toxicus, dont les conclusions troublantes remettent en question notre mode de vie.
Un goûter sera servi aux participants.
Par le Réseau Québécois en reproduction avec la participation de:
- Faculté de Médecine vétérinaire
- Centre de recherche en reproduction animal
- Institut National de la Recherche Scientifique
- Comité En vert et Pour Tous
Le 11 mai 2012 de 12h00 à 14h30 à la Faculté de médecine vétérinaire, Pavillon principal, Local 2135
Réservation nécessaire, avant le 4 mai 2012.
Renseignements et réservation:
Julie Blouin 450-773-8521 p.8221
This email address is being protected from spambots. You need JavaScript enabled to view it.
Michel Fortier
A new discovery links menstrual pain and cardiovascular diseases
Dr. Michel A. Fortier, professor at Université Laval, studies uterine function at the cellular and molecular level in the context of fertility and early pregnancy. In the course of his CIHR funded project on menstrual disorders, he has made an important discovery about prostaglandins – locally-acting hormones that are essential for female reproduction, yet also responsible for inflammation, pain, fever and headaches. Prostaglandins have been the target for treatment with non-steroidal anti-inflammatory drugs such as aspirin and ibuprofen for over a century. One such prostaglandin, PGF2α, is responsible for blood vessel constriction that can lead to menstrual pain and even stroke and heart attacks. While looking for the biological pathway that produces PGF2α in the uterus, Dr. Fortier and his colleagues discovered that the enzyme known as "human aldose reductase" plays an important role in the process of creating PGF2α. The discovery of this enzyme opens up the possibility of entirely new ways to treat not only menstrual pain, but also cardiovascular complications including stroke and heart attack.
Recognizing the importance of this discovery, Dr. Joy Johnson, Scientific Director of the CIHR Institute of Gender and Health, highlights: "It is fascinating that a study of uterine function could lead to new ways to treat cardiac disorders. This research is a testament to the importance of considering the role of biological sex-based factors in influencing seemingly unrelated health issues."
